NOF Tip for 12 May – Safe Movement Brochure

Knowing how to move safely avoids unnecessary risks for falls and fractures.  That can improve your life.  Avoid unnecessary risks. NOF publication https://www.nof.org/wp-content/uploads/Safe-Movement-Brochure-COMBINED.pdf details proper bending, lifting, etc. This brochure...

Improve Bone First – Preserve Bone Second

National Bone Health treatment goals are changing for those patients with high fracture risk.  Simply preserving bones already at a too high fracture risk never made much sense to this...

Evenity is a Really Different Anabolic

We now have a third anabolic medication to build new bone.  Evenity is really different from the other anabolics, Forteo (teriparatide) and Tymlos (abaloparatide).  Forteo and Tymlos are daily shots based...

Treat to Target #6 – Treatment

Our goal is NO NEW FRACTURES.  Therefore, Treat to Target means a FRAX score of <20% for “major osteoporotic” and <3% for hip fracture.  Alternately, T-score of better than -1.5 if...

A New Anabolic – Tymlos

The FDA approved Tymlos (Abaloparatide) in June for use in women diagnosed with osteoporosis.  Unfortunately most patients are unlikely to obtain insurance coverage for Tymlos until January or February 2018. Tymlos...

The Bone Health Guidelines are Changing

University of Wisconsin hosts biennially the Bare Bones of Osteoporosis Care Symposium.  This year the Wisconsin Bone Club followed the symposium. Felicia Cosman, MD from Helen Hayes in New York was the guest...

“Treat to Target” and “Use VFA” in 2017

Clinical Osteoporosis 2017, NOF and ISCD joint meeting had a different emphasis this year.  Fracture Risk, rather than Bone Mineral Density (BMD) is now the key metric.  Several speakers emphasizd...

Use the Anabolic, Forteo, First => Then Use an Antiresorptive

Recent studies have shown that the order in which we use osteoporosis medications matters.  Traditionally most docs have used Antirsorptives first to preserve bone.  All osteoporosis medications except one are Antiresorptives....